ASH 2009 meeting report - Top 10 clinically oriented abstracts in chronic myeloid leukemia

Amber Fullmer, Jorge Cortes, Hagop Kantarjian, Elias Jabbour

Research output: Contribution to journalArticle

Abstract

Chronic myeloid leukemia (CML) is characterized by an acquired chromosomal translocation known as the Philadelphia chromosome. Simple target inhibition specific for Bcr-Abl can control the disease. Outcomes in CML have drastically changed following the introduction of imatinib, with the majority of patients living a normal lifespan. The abstracts presented at the 2009 American Society of Hematology (ASH) annual meeting suggested optimization of current management with new molecules more potent than imatinib and combination therapy with intention to cure CML. The most clinically relevant abstracts in CML, all of which are published in the November 2009; 114 issue of Blood, are summarized below and identified by abstract number.

Original languageEnglish (US)
Pages (from-to)283-286
Number of pages4
JournalAmerican Journal of Hematology
Volume85
Issue number4
DOIs
StatePublished - Apr 1 2010
Externally publishedYes

Fingerprint

Hematology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Philadelphia Chromosome
Genetic Translocation
Imatinib Mesylate
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

ASH 2009 meeting report - Top 10 clinically oriented abstracts in chronic myeloid leukemia. / Fullmer, Amber; Cortes, Jorge; Kantarjian, Hagop; Jabbour, Elias.

In: American Journal of Hematology, Vol. 85, No. 4, 01.04.2010, p. 283-286.

Research output: Contribution to journalArticle

Fullmer, Amber ; Cortes, Jorge ; Kantarjian, Hagop ; Jabbour, Elias. / ASH 2009 meeting report - Top 10 clinically oriented abstracts in chronic myeloid leukemia. In: American Journal of Hematology. 2010 ; Vol. 85, No. 4. pp. 283-286.
@article{bc5699c8e44c4293b96885ab0abe493f,
title = "ASH 2009 meeting report - Top 10 clinically oriented abstracts in chronic myeloid leukemia",
abstract = "Chronic myeloid leukemia (CML) is characterized by an acquired chromosomal translocation known as the Philadelphia chromosome. Simple target inhibition specific for Bcr-Abl can control the disease. Outcomes in CML have drastically changed following the introduction of imatinib, with the majority of patients living a normal lifespan. The abstracts presented at the 2009 American Society of Hematology (ASH) annual meeting suggested optimization of current management with new molecules more potent than imatinib and combination therapy with intention to cure CML. The most clinically relevant abstracts in CML, all of which are published in the November 2009; 114 issue of Blood, are summarized below and identified by abstract number.",
author = "Amber Fullmer and Jorge Cortes and Hagop Kantarjian and Elias Jabbour",
year = "2010",
month = "4",
day = "1",
doi = "10.1002/ajh.21662",
language = "English (US)",
volume = "85",
pages = "283--286",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - ASH 2009 meeting report - Top 10 clinically oriented abstracts in chronic myeloid leukemia

AU - Fullmer, Amber

AU - Cortes, Jorge

AU - Kantarjian, Hagop

AU - Jabbour, Elias

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Chronic myeloid leukemia (CML) is characterized by an acquired chromosomal translocation known as the Philadelphia chromosome. Simple target inhibition specific for Bcr-Abl can control the disease. Outcomes in CML have drastically changed following the introduction of imatinib, with the majority of patients living a normal lifespan. The abstracts presented at the 2009 American Society of Hematology (ASH) annual meeting suggested optimization of current management with new molecules more potent than imatinib and combination therapy with intention to cure CML. The most clinically relevant abstracts in CML, all of which are published in the November 2009; 114 issue of Blood, are summarized below and identified by abstract number.

AB - Chronic myeloid leukemia (CML) is characterized by an acquired chromosomal translocation known as the Philadelphia chromosome. Simple target inhibition specific for Bcr-Abl can control the disease. Outcomes in CML have drastically changed following the introduction of imatinib, with the majority of patients living a normal lifespan. The abstracts presented at the 2009 American Society of Hematology (ASH) annual meeting suggested optimization of current management with new molecules more potent than imatinib and combination therapy with intention to cure CML. The most clinically relevant abstracts in CML, all of which are published in the November 2009; 114 issue of Blood, are summarized below and identified by abstract number.

UR - http://www.scopus.com/inward/record.url?scp=77950425887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950425887&partnerID=8YFLogxK

U2 - 10.1002/ajh.21662

DO - 10.1002/ajh.21662

M3 - Article

AN - SCOPUS:77950425887

VL - 85

SP - 283

EP - 286

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 4

ER -